🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 24/11/2004 | 10,80 | 11,08 | 10,74 | 10,87 | +0,18% | 3,15% | 442.800 |
| 23/11/2004 | 10,95 | 10,99 | 10,42 | 10,85 | -0,09% | 5,21% | 398.100 |
| 22/11/2004 | 10,29 | 10,90 | 10,15 | 10,86 | +3,53% | 7,29% | 542.400 |
| 19/11/2004 | 10,77 | 10,96 | 10,49 | 10,49 | -2,69% | 4,36% | 416.800 |
| 18/11/2004 | 10,57 | 10,96 | 10,30 | 10,78 | +1,22% | 6,24% | 541.700 |
| 17/11/2004 | 11,01 | 11,37 | 10,56 | 10,65 | -4,66% | 7,36% | 926.700 |
| 16/11/2004 | 11,50 | 11,69 | 10,84 | 11,17 | -4,45% | 7,39% | 766.200 |
| 15/11/2004 | 11,66 | 11,74 | 11,50 | 11,69 | -0,43% | 2,06% | 396.300 |
| 12/11/2004 | 11,99 | 12,05 | 11,50 | 11,74 | -1,43% | 4,59% | 655.300 |
| 11/11/2004 | 11,51 | 12,00 | 11,30 | 11,91 | +3,75% | 6,08% | 523.100 |
| 10/11/2004 | 11,65 | 11,73 | 11,27 | 11,48 | +0,17% | 3,95% | 371.700 |
| 09/11/2004 | 11,23 | 11,53 | 11,06 | 11,46 | +2,50% | 4,19% | 369.200 |
| 08/11/2004 | 11,14 | 11,20 | 10,96 | 11,18 | -1,15% | 2,15% | 524.900 |
| 05/11/2004 | 10,84 | 11,40 | 10,81 | 11,31 | +2,82% | 5,44% | 454.700 |
| 04/11/2004 | 11,43 | 11,50 | 10,82 | 11,00 | -3,68% | 5,95% | 918.800 |
| 03/11/2004 | 11,16 | 11,60 | 11,04 | 11,42 | +5,35% | 5,02% | 492.900 |
| 02/11/2004 | 11,55 | 11,64 | 10,83 | 10,84 | -5,49% | 7,01% | 819.600 |
| 01/11/2004 | 10,84 | 11,50 | 10,64 | 11,47 | +5,42% | 7,93% | 1.022.700 |
| 29/10/2004 | 10,70 | 10,95 | 10,56 | 10,88 | +1,21% | 3,64% | 441.000 |
| 28/10/2004 | 10,49 | 10,87 | 10,47 | 10,75 | +2,87% | 3,81% | 485.400 |
| 27/10/2004 | 10,26 | 10,60 | 10,14 | 10,45 | +3,57% | 4,48% | 753.000 |
| 26/10/2004 | 10,17 | 10,33 | 9,91 | 10,09 | -1,37% | 4,13% | 810.700 |
| 25/10/2004 | 9,85 | 10,36 | 9,79 | 10,23 | +2,20% | 5,79% | 442.800 |
| 22/10/2004 | 10,56 | 10,62 | 10,01 | 10,01 | -3,75% | 5,78% | 415.100 |
| 21/10/2004 | 10,44 | 10,54 | 10,15 | 10,40 | -0,67% | 3,74% | 550.600 |
| 20/10/2004 | 10,21 | 10,50 | 10,08 | 10,47 | +2,25% | 4,11% | 410.000 |
| 19/10/2004 | 10,49 | 10,57 | 10,22 | 10,24 | -2,01% | 3,34% | 534.500 |
| 18/10/2004 | 10,48 | 10,56 | 10,19 | 10,45 | +1,26% | 3,53% | 500.300 |
| 15/10/2004 | 10,37 | 10,51 | 10,10 | 10,32 | +1,38% | 3,95% | 864.500 |
| 14/10/2004 | 10,05 | 10,28 | 9,99 | 10,18 | +0,89% | 2,89% | 559.300 |